AR064072A1 - Combinacion para el tratamiento de una enfermedad proliferativa - Google Patents
Combinacion para el tratamiento de una enfermedad proliferativaInfo
- Publication number
- AR064072A1 AR064072A1 ARP070105351A ARP070105351A AR064072A1 AR 064072 A1 AR064072 A1 AR 064072A1 AR P070105351 A ARP070105351 A AR P070105351A AR P070105351 A ARP070105351 A AR P070105351A AR 064072 A1 AR064072 A1 AR 064072A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- treatment
- metabolite
- refers
- mds
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 230000000340 anti-metabolite Effects 0.000 abstract 3
- 229940100197 antimetabolite Drugs 0.000 abstract 3
- 239000002256 antimetabolite Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 abstract 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La solicitud se refiere a una combinacion que comprende: (a) un inhibidor de desacetilasa de histona (HDAI); y (b) un anti-metabolito, para su uso simultáneo, concurrente, separado, o en secuencia, en especial para utilizarse en el tratamiento de enfermedades proliferativas, más específicamente MDS o AML. La presente también se refiere a composiciones farmacéuticas que comprenden esta combinacion, y a un método para el tratamiento de MDS o AML, en un mamífero, en particular un ser humano, con esta combinacion. La presente también se refiere además a un paquete o producto comercial que comprende dicha combinacion. Reivindicacion 3: Un método de acuerdo con la reivindicacion 1, en donde la HDAC es N-hidroxi-3-[4-[[[2-(2-metil-1H-indol- 3-il)-etil]-amino]- metil]-fenil]-2E-2-propenamida, o una sal farmacéuticamente aceptable de la misma, en combinacion con (b) un anti-metabolito. Reivindicacion 4: Un método de acuerdo con la reivindicacion 1, en donde el anti-metabolito es 5- azacitidina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86838806P | 2006-12-04 | 2006-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064072A1 true AR064072A1 (es) | 2009-03-11 |
Family
ID=39272127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105351A AR064072A1 (es) | 2006-12-04 | 2007-11-30 | Combinacion para el tratamiento de una enfermedad proliferativa |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8093220B2 (es) |
| EP (1) | EP2099451B1 (es) |
| JP (3) | JP5784274B2 (es) |
| KR (1) | KR101475538B1 (es) |
| CN (1) | CN101553223A (es) |
| AR (1) | AR064072A1 (es) |
| AU (1) | AU2007328281B2 (es) |
| BR (1) | BRPI0719746A2 (es) |
| CA (1) | CA2670741C (es) |
| CL (1) | CL2007003467A1 (es) |
| EC (1) | ECSP099483A (es) |
| ES (1) | ES2569477T3 (es) |
| GT (1) | GT200900148A (es) |
| IL (1) | IL198638A (es) |
| MA (1) | MA30982B1 (es) |
| MX (1) | MX2009005946A (es) |
| MY (1) | MY148893A (es) |
| NO (1) | NO20092473L (es) |
| PE (1) | PE20081303A1 (es) |
| PL (1) | PL2099451T3 (es) |
| RU (1) | RU2469717C2 (es) |
| TN (1) | TN2009000213A1 (es) |
| TW (1) | TW200831075A (es) |
| WO (1) | WO2008070011A2 (es) |
| ZA (1) | ZA200903041B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102036955B (zh) | 2008-03-26 | 2013-03-27 | 诺瓦提斯公司 | 脱乙酰酶b的异羟肟酸盐为基础的抑制剂 |
| EP2306996A1 (en) * | 2008-07-18 | 2011-04-13 | Novartis AG | Use of hdac inhibitors for the treatment of hodgkin's disease |
| WO2010009285A1 (en) * | 2008-07-18 | 2010-01-21 | Novartis Ag | Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome |
| US20110053925A1 (en) * | 2009-08-28 | 2011-03-03 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
| MY166014A (en) * | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| RU2013114246A (ru) * | 2010-09-01 | 2014-10-20 | Новартис Аг | Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении |
| EP2968282B1 (en) | 2013-03-12 | 2018-05-09 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
| WO2015078929A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
| CN107001330A (zh) | 2014-09-17 | 2017-08-01 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| EA201792028A1 (ru) | 2015-03-13 | 2018-04-30 | Форма Терапьютикс, Инк. | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| AU2004241729A1 (en) | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
-
2007
- 2007-11-30 WO PCT/US2007/024712 patent/WO2008070011A2/en not_active Ceased
- 2007-11-30 AU AU2007328281A patent/AU2007328281B2/en not_active Ceased
- 2007-11-30 MY MYPI20091975A patent/MY148893A/en unknown
- 2007-11-30 KR KR1020097013917A patent/KR101475538B1/ko not_active Expired - Fee Related
- 2007-11-30 CA CA2670741A patent/CA2670741C/en not_active Expired - Fee Related
- 2007-11-30 US US12/516,656 patent/US8093220B2/en not_active Expired - Fee Related
- 2007-11-30 RU RU2009125439/15A patent/RU2469717C2/ru not_active IP Right Cessation
- 2007-11-30 CN CNA2007800429689A patent/CN101553223A/zh active Pending
- 2007-11-30 BR BRPI0719746-2A2A patent/BRPI0719746A2/pt not_active IP Right Cessation
- 2007-11-30 AR ARP070105351A patent/AR064072A1/es unknown
- 2007-11-30 EP EP07862420.2A patent/EP2099451B1/en active Active
- 2007-11-30 PE PE2007001696A patent/PE20081303A1/es not_active Application Discontinuation
- 2007-11-30 PL PL07862420T patent/PL2099451T3/pl unknown
- 2007-11-30 ES ES07862420.2T patent/ES2569477T3/es active Active
- 2007-11-30 MX MX2009005946A patent/MX2009005946A/es active IP Right Grant
- 2007-11-30 JP JP2009540242A patent/JP5784274B2/ja not_active Expired - Fee Related
- 2007-12-03 TW TW096145961A patent/TW200831075A/zh unknown
- 2007-12-03 CL CL200703467A patent/CL2007003467A1/es unknown
-
2009
- 2009-05-04 ZA ZA200903041A patent/ZA200903041B/xx unknown
- 2009-05-07 IL IL198638A patent/IL198638A/en active IP Right Grant
- 2009-05-29 TN TNP2009000213A patent/TN2009000213A1/fr unknown
- 2009-06-03 GT GT200900148A patent/GT200900148A/es unknown
- 2009-06-10 MA MA31973A patent/MA30982B1/fr unknown
- 2009-06-30 NO NO20092473A patent/NO20092473L/no not_active Application Discontinuation
- 2009-07-03 EC EC2009009483A patent/ECSP099483A/es unknown
-
2013
- 2013-12-26 JP JP2013269307A patent/JP2014097992A/ja active Pending
-
2015
- 2015-07-21 JP JP2015144342A patent/JP2016006070A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064072A1 (es) | Combinacion para el tratamiento de una enfermedad proliferativa | |
| ES2611483T3 (es) | Agente terapéutico para enfermedad inflamatoria intestinal | |
| CL2007003108A1 (es) | Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington, | |
| BRPI0410648A (pt) | combinação de inibidores de histona desacetilase com agentes quimioterápicos | |
| AR062721A1 (es) | Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla | |
| TN2009000344A1 (en) | Combinations of therapeutic agents for treating cancer | |
| CL2007002574A1 (es) | Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson. | |
| CR8163A (es) | Composicion farmaceutica que contiene un inhibidor de histona desacetilasa | |
| MX378867B (es) | Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular. | |
| CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
| CL2007003874A1 (es) | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio | |
| BRPI1011236A2 (pt) | métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) | |
| CL2007000345A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes. | |
| GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
| ES2383822T3 (es) | Formulaciones para el tratamiento de anomalías de lipoproteínas que comprenden una estatina y un derivado de metilnicotinamida | |
| BRPI0807940B8 (pt) | usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido | |
| Lahoti et al. | Evaluation of the analgesic and anti-inflammatory activity of fixed dose combination: non-steroidal anti-inflammatory drugs in experimental animals | |
| EP2251016A3 (en) | Topical use of hyaluronic acid with folmogenic action for the treatment and prophylaxys of pathologies of the respiratory tract. | |
| CR10253A (es) | "inhibidores de pai-1 para tratamiento de afecciones musculares" | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
| PL4110781T3 (pl) | Związki pochodne 1,3,4 oksadiazolu jako inhibitor deacetylazy histonowej 6 oraz zawierająca je kompozycja farmaceutyczna | |
| AR083693A1 (es) | Formulacion del inhibidor de proteina de transferencia del ester de colesterilo (inhibidor de la cetp), tableta, uso, proceso, kit | |
| CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. | |
| AR061477A1 (es) | Metodos para utilizar un derivado de tiazol | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |